Deep Track Capital CBIO Position
Active8-Fund ConvergenceDeep Track Capital held their position in CRESCENT BIOPHARMA, INC. (CBIO) in Q4 2025, holding $5.4M worth of shares across 453,686 shares.
The position was first reported in Q2 2025 and has been tracked across 3 quarterly 13F filings.
CBIO is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for CR-001 in 1049 days (Feb 28, 2029), making the timing of Deep Track's position particularly relevant.
Short interest stands at 12.0% of float with 8.5 days to cover, indicating significant bearish positioning against Deep Track's long thesis.
About CRESCENT BIOPHARMA, INC.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
Full company profile →Short Interest
12.0%
8.5 days to cover
Deep Track Capital CBIO Position History
Frequently Asked Questions
Does Deep Track Capital own CBIO?
Yes. As of Q4 2025, Deep Track Capital holds 453,686 shares of CRESCENT BIOPHARMA, INC. (CBIO) valued at $5.4M. This data comes from their SEC 13F filing.
How many hedge funds own CBIO?
8 specialist biotech hedge funds currently hold CBIO, including BVF Partners, Tang Capital Management, Perceptive Advisors and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deep Track Capital first buy CBIO?
Deep Track Capital's position in CBIO was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deep Track Capital's CBIO position increasing or decreasing?
Deep Track Capital held their CBIO position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CBIOCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deep Track CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →